Clinical experience with platelet-activating factor antagonists. Past, present, and near future.

No abstract is available for this paper.

• Publication year

  1994

• Venue

  Clinical Reviews in Allergy

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 7743464
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Inhibitory effect of oral WEB 2086, a novel selective PAF-acether antagonist, on ex vivo platelet aggregation

  2004cited by this paper
• The metabolic effects of platelet-activating factor antagonism in endotoxemic man.

  1994cited by this paper
• Effect of the platelet-activating factor antagonist UK-74,505 on the early and late response to allergen.

  1993cited by this paper
• Effect of a platelet activating factor antagonist, WEB 2086, on allergen induced asthmatic responses.

  1993cited by this paper
• FMLP causes eicosanoid-dependent vasoconstriction and edema in lungs from endotoxin-primed rats.

  1992cited by this paper
• Role of PAF and cytokines in microvascular tissue injury.

  1992cited by this paper
• Time course of various inflammatory mediators during recurrent endotoxemia.

  1992cited by this paper
• [Pilot study of Ginkgolide B, a PAF-acether specific inhibitor in the treatment of acute outbreaks of multiple sclerosis].

  1992cited by this paper
• Inflammatory host responses in sepsis.

  1992cited by this paper
• WEB2170, a specific platelet-activating factor antagonist, attenuates neutrophil priming by human serum after clinical burn injury: the 1991 Moyer Award.

  1991cited by this paper
• Platelet-activating factor type activity in plasma from patients with septicemia and other diseases

  1991cited by this paper
• The effect of inhaled corticosteroids on the maximal degree of airway narrowing to methacholine in asthmatic subjects.

  1991cited by this paper
• Recent progress in ginkgolide research

  1991cited by this paper
• Granulocyte-macrophage colony-stimulating factor increases the synthesis of leukotriene B4 by human neutrophils in response to platelet-activating factor. Enhancement of both arachidonic acid availability and 5-lipoxygenase activation.

  1991cited by this paper
• Effect of platelet-activating factor on tumor necrosis factor-induced superoxide generation from human neutrophils. Possible involvement of G proteins

  1991cited by this paper
• Platelet activating factor is one of the mediators involved in endotoxic shock in pigs.

  1991cited by this paper
• A PAF receptor antagonist, BN 52021, attenuates thromboxane release and improves survival in lethal canine endotoxemia.

  1991cited by this paper
• Role of free radicals and platelet-activating factor in the genesis of intestinal motor disturbances induced by Escherichia coli endotoxins in rats.

  1991cited by this paper
• The proinflammatory cytokines interleukin-1 and tumor necrosis factor and treatment of the septic shock syndrome.

  1991cited by this paper
• Inhibition of cutaneous and platelet responses to platelet-activating factor by oral WEB 2086 in man.

  1991cited by this paper
• Effects of PAF antagonist, BN52021, on the PAF-, methacholine-, and allergen-induced bronchoconstriction in asthmatic children.

  1991cited by this paper
• Pharmacodynamics, pharmacokinetics and safety profile of the new platelet-activating factor antagonist apafant in man.

  1991cited by this paper
• The role of platelet activating factor and its antagonists in shock, sepsis and multiple organ failure.

  1991cited by this paper
• Septic shock: pathogenesis.

  1991cited by this paper
• Effect of SRI 63-675 on hemodynamics and blood PAF levels during porcine endotoxemia.

  1991cited by this paper
• Septic shock.

  1991cited by this paper
• Sequential release of tumour necrosis factor, platelet activating factor and eicosanoids during endotoxin shock in anaesthetized pigs; protective effects of indomethacin

  1991cited by this paper
• Platelet activating factor (PAF) and tumor necrosis factor-alpha (TNF alpha) interactions in endotoxemic shock: studies with BN 50739, a novel PAF antagonist.

  1990cited by this paper
• Platelet activating factor receptor antagonist improves survival and attenuates eicosanoid release in severe endotoxemia.

  1990cited by this paper
• Tumor necrosis factor alpha 'primes' the platelet-activating factor-induced superoxide production by human neutrophils: possible involvement of G proteins.

  1990cited by this paper
• Protective effect of BN 50739, a new platelet-activating factor antagonist, in endotoxin-treated rabbits.

  1990cited by this paper
• Effect of long-term treatment with platelet-activating factor on IL-1 and IL-2 production by rat spleen cells.

  1990cited by this paper
• Effects of endothelin on the lethality induced by platelet-activating factor or endotoxin in the mouse.

  1990cited by this paper
• Contribution of platelet activating factor to hemodynamic and sympathetic responses to bacterial endotoxin in conscious rats.

  1990cited by this paper
• Platelet activating factor-induced clinical and histopathologic responses in atopic skin and their modification by the platelet activating factor antagonist BN52063.

  1990cited by this paper
• Inhibitory effects of the new PAF acether antagonist WEB‐2086 on pharmacologic changes induced by PAF inhalation in human beings

  1990cited by this paper
• Endotoxin-induced impairment of vascular reactivity in the pithed rat: role of arachidonic acid metabolites.

  1990cited by this paper
• Is there a case for PAF antagonists in the treatment of ischemic states?

  1989cited by this paper
• Safety, tolerability., and pharmacologic activity of multiple doses of the new platelet activating factor antagonist WEB 2086 in human subjects

  1989cited by this paper
• PAF-induced platelet aggregation ex vivo as a method for monitoring pharmacological activity in healthy volunteers.

  1989cited by this paper
• PAF/cytokine auto-generated feedback networks in microvascular immune injury: consequences in shock, ischemia and graft rejection.

  1989cited by this paper
• Platelet-activating factor in organ transplant rejection.

  1989cited by this paper
• Multiple sclerosis: Possible immunological mechanisms☆

  1989cited by this paper
• RP 55778, a PAF receptor antagonist, prevents and reverses LPS-induced hemoconcentration and TNF release.

  1989cited by this paper
• LOCALIZATION OF A FACTOR VIII BINDING DOMAIN ON THE N-TERMINAL PORTION (FRAGMENT SpIII) OF VON WILLEBRAND FACTOR

  1988cited by this paper
• Treatment of adult systemic mastocytosis with a PAF-acether antagonist BN52063.

  1988cited by this paper
• Protection of platelet-activating factor-induced acute renal failure by BN 52021.

  1988cited by this paper
• Effect of a PAF antagonist, BN52063, on antigen-induced, acute, and late-onset cutaneous responses in atopic subjects.

  1988cited by this paper
• Role of platelet-activating factor in ulcerative colitis. Enhanced production during active disease and inhibition by sulfasalazine and prednisolone.

  1988cited by this paper
• Attenuation of burn-induced changes in hemodynamics and glucose metabolism by the PAF antagonist SRI 63-675.

  1988cited by this paper
• Attenuation of endotoxin-induced increase in glucose metabolism by platelet-activating factor antagonist.

  1987cited by this paper
• Effect of a ginkgolide mixture (BN 52063) in antagonising skin and platelet responses to platelet activating factor in man.

  1987cited by this paper
• Lymphokines.

  1987cited by this paper
• Platelet‐activating factor: an endogenous mediator for bowel necrosis in endotoxemia

  1987cited by this paper
• Effect of BN 52063, a specific PAF-acether antagonist, on bronchial provocation test to allergens in asthmatic patients. A preliminary study.

  1987cited by this paper
• Shock and tissue injury induced by recombinant human cachectin.

  1986cited by this paper
• Prolongation of cardiac allograft survival with BN 52021, a specific antagonist of platelet-activating factor.

  1986cited by this paper
• Inhibition of PAF-acether induced weal and flare reaction in man by a specific PAF antagonist.

  1986cited by this paper
• Interleukin 1 stimulates platelet-activating factor production in cultured human endothelial cells.

  1986cited by this paper
• RENAL ALLOGRAFT CELL INFILTRATES ASSOCIATED WITH IRREVERSIBLE REJECTION

  1985cited by this paper
• Prolongation of cardiac allograft survival with the PAF antagonist BN-52021 and the thromboxane receptor antagonists L640035 and L636499.

  1985cited by this paper
• Hyperacute renal allograft rejection in the rabbit. The role of platelet-activating factor and of cationic proteins derived from polymorphonuclear leukocytes and from platelets.

  1984cited by this paper
• Acute circulatory collapse caused by platelet-activating factor (PAF-acether) in dogs.

  1983cited by this paper

• Ginkgolide B Regulates CDDP Chemoresistance in Oral Cancer via the Platelet-Activating Factor Receptor Pathway

  2021cites this paper
• Identification of the in vivo relevant dissolution media for the three active components in EGb 761 tablet for better correlation with their pharmacokinetics in healthy subjects.

  2020cites this paper
• Pharmacological action and mechanisms of ginkgolide B.

  2007cites this paper
• The CNS effects of Ginkgo biloba extracts and ginkgolide B.

  2002cites this paper
• Platelet-activating factor in infants at risk for necrotizing enterocolitis.

  2001cites this paper
• Dual antagonists of platelet activating factor and histamine. 3. Synthesis, biological activity and conformational implications of substituted N-acyl-bis-arylcycloheptapiperazines.

  1998cites this paper
• The role of plant-derived drugs and herbal medicines in healthcare.

  1997cites this paper
• The Role of Plant-Derived Drugs and Herbal Medicines in Healthcare

  1997cites this paper